Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gibbons

Showing results (351-360 of 470) with videos related to

Pageof 47
Sort By:
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 4, 2026
Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum DisorderJoao Vitor Mahler, Gerome B Vallejos, Takahisa Mikami, et al.
Cell Reports. Medicine|March 12, 2024
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of conceptMorteza Salehjahromi, Tatiana V Karpinets, Sheeba J Sujit, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLCPierre-Olivier Gaudreau, Marcelo V Negrao, Kyle G Mitchell, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2021
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancerL Federico, D J McGrail, S-E Bentebibel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyM M Zheng, Y Xia, K Pan, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Pageof 47

Showing results (351-360 of 470) with videos related to

Sort By:
Pageof 47
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 4, 2026
Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum DisorderJoao Vitor Mahler, Gerome B Vallejos, Takahisa Mikami, et al.
Cell Reports. Medicine|March 12, 2024
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of conceptMorteza Salehjahromi, Tatiana V Karpinets, Sheeba J Sujit, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLCPierre-Olivier Gaudreau, Marcelo V Negrao, Kyle G Mitchell, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2021
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancerL Federico, D J McGrail, S-E Bentebibel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyM M Zheng, Y Xia, K Pan, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Pageof 47